CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Low bargaining power of suppliers
3.3.2. Low threat of new entrants
3.3.3. Low threat of substitutes
3.3.4. Low intensity of rivalry
3.3.5. Low bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Surge in adoption of generative AI in healthcare in medical imaging.
3.4.1.2. Efficiency of generative AI in workflow and administrative tasks.
3.4.1.3. Use of generative AI in personalized medicine.
3.4.2. Restraints
3.4.2.1. Data privacy and security risk.
3.4.3. Opportunities
3.4.3.1. Use of generative AI in drug discovery development
CHAPTER 4: GENERATIVE AI IN HEALTHCARE MARKET, BY APPLICATION
4.1. Overview
4.1.1. Market size and forecast
4.2. Treatment
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Diagnosis
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Drug Discovery
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Research
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
CHAPTER 5: GENERATIVE AI IN HEALTHCARE MARKET, BY END USER
5.1. Overview
5.1.1. Market size and forecast
5.2. Hospitals and clinics
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Healthcare Organizations
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Others
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: GENERATIVE AI IN HEALTHCARE MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast By Region
6.2. North America
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by Application
6.2.3. Market size and forecast, by End User
6.2.4. Market size and forecast, by country
6.2.4.1. U.S.
6.2.4.1.1. Market size and forecast, by Application
6.2.4.1.2. Market size and forecast, by End User
6.2.4.2. Canada
6.2.4.2.1. Market size and forecast, by Application
6.2.4.2.2. Market size and forecast, by End User
6.2.4.3. Mexico
6.2.4.3.1. Market size and forecast, by Application
6.2.4.3.2. Market size and forecast, by End User
6.3. Europe
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by Application
6.3.3. Market size and forecast, by End User
6.3.4. Market size and forecast, by country
6.3.4.1. Germany
6.3.4.1.1. Market size and forecast, by Application
6.3.4.1.2. Market size and forecast, by End User
6.3.4.2. France
6.3.4.2.1. Market size and forecast, by Application
6.3.4.2.2. Market size and forecast, by End User
6.3.4.3. UK
6.3.4.3.1. Market size and forecast, by Application
6.3.4.3.2. Market size and forecast, by End User
6.3.4.4. Italy
6.3.4.4.1. Market size and forecast, by Application
6.3.4.4.2. Market size and forecast, by End User
6.3.4.5. Spain
6.3.4.5.1. Market size and forecast, by Application
6.3.4.5.2. Market size and forecast, by End User
6.3.4.6. Rest of Europe
6.3.4.6.1. Market size and forecast, by Application
6.3.4.6.2. Market size and forecast, by End User
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by Application
6.4.3. Market size and forecast, by End User
6.4.4. Market size and forecast, by country
6.4.4.1. Japan
6.4.4.1.1. Market size and forecast, by Application
6.4.4.1.2. Market size and forecast, by End User
6.4.4.2. China
6.4.4.2.1. Market size and forecast, by Application
6.4.4.2.2. Market size and forecast, by End User
6.4.4.3. Australia
6.4.4.3.1. Market size and forecast, by Application
6.4.4.3.2. Market size and forecast, by End User
6.4.4.4. India
6.4.4.4.1. Market size and forecast, by Application
6.4.4.4.2. Market size and forecast, by End User
6.4.4.5. South Korea
6.4.4.5.1. Market size and forecast, by Application
6.4.4.5.2. Market size and forecast, by End User
6.4.4.6. Rest of Asia-Pacific
6.4.4.6.1. Market size and forecast, by Application
6.4.4.6.2. Market size and forecast, by End User
6.5. LAMEA
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by Application
6.5.3. Market size and forecast, by End User
6.5.4. Market size and forecast, by country
6.5.4.1. Brazil
6.5.4.1.1. Market size and forecast, by Application
6.5.4.1.2. Market size and forecast, by End User
6.5.4.2. Saudi Arabia
6.5.4.2.1. Market size and forecast, by Application
6.5.4.2.2. Market size and forecast, by End User
6.5.4.3. South Africa
6.5.4.3.1. Market size and forecast, by Application
6.5.4.3.2. Market size and forecast, by End User
6.5.4.4. Rest of LAMEA
6.5.4.4.1. Market size and forecast, by Application
6.5.4.4.2. Market size and forecast, by End User
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product mapping of top 10 player
7.4. Competitive dashboard
7.5. Competitive heatmap
7.6. Top player positioning, 2022
CHAPTER 8: COMPANY PROFILES
8.1. Syntegra
8.1.1. Company overview
8.1.2. Key executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Key strategic moves and developments
8.2. IBM Watson Health Corporation
8.2.1. Company overview
8.2.2. Key executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.2.6. Business performance
8.3. Google LLC
8.3.1. Company overview
8.3.2. Key executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.3.6. Business performance
8.3.7. Key strategic moves and developments
8.4. Amazon
8.4.1. Company overview
8.4.2. Key executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.5. Oracle
8.5.1. Company overview
8.5.2. Key executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.5.6. Business performance
8.6. Microsoft
8.6.1. Company overview
8.6.2. Key executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.6.6. Business performance
8.6.7. Key strategic moves and developments
8.7. NVIDIA Corporation
8.7.1. Company overview
8.7.2. Key executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.7.6. Business performance
8.7.7. Key strategic moves and developments
8.8. InSilico Medicine
8.8.1. Company overview
8.8.2. Key executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.9. Abridge AI Inc.
8.9.1. Company overview
8.9.2. Key executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.10. Open AI Inc.
8.10.1. Company overview
8.10.2. Key executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
| ※参考情報 医療における生成AIは、医療分野でのデータ生成や情報処理を行う人工知能(AI)の一種です。生成AIは、既存のデータをもとに新しいデータを生成する能力を持ち、特に画像、音声、テキストなど多様な形式での応用が期待されています。この技術は、医療のさまざまな領域に革命をもたらす可能性があります。 生成AIの種類としては、主に生成対向ネットワーク(GAN)、変分オートエンコーダ(VAE)、トランスフォーマーモデルなどがあります。GANは、敵対的に学習する二つのネットワークを用いて新しいデータを生成します。VAEは、データの潜在変数を捉え、その情報を元に新しいデータを生成する技術です。トランスフォーマーモデルは、特にテキスト生成に強く、自然言語処理の分野での応用が進んでいます。 生成AIの用途は多岐にわたります。まず、医療画像の生成が挙げられます。CTスキャンやMRI画像などの医療画像を生成・補完することで、より多くのデータを得られ、診断精度が向上します。また、データの不足が課題となるRare Diseaseの研究などにおいて、生成AIは不足するデータを補う役割を果たします。 次に、生成AIは治療計画の支援にも使われます。患者の状態に応じた最適な治療法を提案するためのシミュレーションを行うことが可能となり、より個別化された医療を実現します。さらに、電子カルテから得られるテキストデータを分析し、診断や予後の予測に活用することもできます。 生成AIは、医療研究にも大きな影響を与えています。新薬の候補化合物を生成することにより、開発期間を短縮し、コストを削減する効果があります。この技術により、より早く安全な薬が市場に出る可能性が広がります。また、疫学研究においては、シミュレーションデータを生成することで、感染症の流行予測や治療効果の分析にも貢献しています。 関連技術としては、機械学習やディープラーニングが挙げられます。生成AIは、これらの技術を活用して学習を行い、データからパターンを見出します。医療に特化したデータセットで学べることにより、生成AIはより信頼性の高い結果を提供できます。 さらに、ブロックチェーン技術との連携も期待されています。医療データの安全な管理や共有を行うために、生成AIとブロックチェーンの組み合わせにより、データの信頼性と透明性を確保することができるでしょう。 最後に、エシックスやプライバシーの問題も重要です。生成AIが生成するデータには個人情報が含まれる可能性があるため、その取り扱いに注意が必要です。データの匿名化や、適切な利用に関するガイドラインの策定が求められています。 このように、医療における生成AIは、写実的なデータ生成から個別化医療の推進、さらには研究開発に至るまで幅広い分野で応用可能です。将来的には、医療従事者の負担軽減と患者にとってのより良い医療提供につながることが期待されています。生成AIの発展は、医療業界における革新を加速させ、私たちの健康管理に新たな可能性をもたらします。 |
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/

